Thai producer of AstraZeneca vaccine passes quality test

Thailand and the region are about to get a booster shot of COVID-19 vaccine supply as the first batches of the AstraZeneca vaccine produced by Siam Bioscience have passed quality tests in labs in the United States and Europe.

“I am happy to be able to inform you that the samples from the test batches of the COVID-19 vaccine made by Siam Bioscience had passed the quality testing at AstraZeneca’s designated laboratories in Europe and in the U.S.,” said James Teague, Country President, AstraZeneca (Thailand).

“This significant progress means that we are getting closer to delivering the first batch of the vaccine to the Government of Thailand,” Teague said.

Thai public health officials have said that the full national vaccine rollout will start in June. Prime Minister Prayut Chan-o-cha has vowed to have half the Thai population vaccinated by the end of this year.

Siam Bioscience is a private company founded in 2009 to fill gaps in medical research and technology in the Kingdom.

In addition, the Thailand vaccine production facility, critical to not only the Thailand Government’s fight against the pandemic but also to other Southeast Asian countries the plant will export to, has passed the Good Manufacturing Practice (GMP), a system ensuring that products are consistently produced and controlled according to quality standards.

“Thailand will play a central role to support our neighbors in Southeast Asia to combat COVID-19, together we can hold hands to fight this pandemic,” said Mr. Teague.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Photo Courtesy of